이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

REGENXBIO 대차 대조표 상태

재무 상태 기준 확인 5/6

REGENXBIO 의 총 주주 지분은 $390.7M 이고 총 부채는 $83.3M, 이는 부채 대 자기자본 비율을 21.3% 로 가져옵니다. 총자산과 총부채는 각각 $629.2M 및 $238.5M 입니다.

주요 정보

21.3%

부채 비율

US$83.32m

부채

이자 보상 비율	n/a
현금	US$338.70m
주식	US$390.67m
총 부채	US$238.55m
총 자산	US$629.22m

최근 재무 상태 업데이트

Recent updates

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Aug 08

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Oct 03

Regenxbio: A Transformative Year

Sep 15

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Aug 29

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Aug 03

재무 상태 분석

단기부채: RGNX 의 단기 자산 ( $395.4M )이 단기 부채( $110.2M ).

장기 부채: RGNX 의 단기 자산( $395.4M )이 장기 부채( $128.4M ).

부채 대 자본 내역 및 분석

부채 수준: RGNX 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: RGNX 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 21.3% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: RGNX 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: RGNX 24.4 1 24.4 % 매년.

REGENXBIO 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

Recent updates

REGENXBIO Inc. Announces Expansion of Affinity Duchenne Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Inc. Announces Chief Executive Officer Changes

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

President notifies of intention to sell stock

Consensus revenue estimates fall by 27%

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

First quarter 2024 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

President exercised options and sold US$272k worth of stock

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Price target increased by 7.3% to US$38.55

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

President exercised options and sold US$195k worth of stock

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

President notifies of intention to sell stock

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Consensus revenue estimates fall by 16%

Executive VP & Chief Medical Officer notifies of intention to sell stock

President notifies of intention to sell stock

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Price target decreased by 10% to US$36.40

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Consensus EPS estimates upgraded to US$4.84 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Consensus EPS estimates fall by 19%

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Consensus EPS estimates upgraded to US$4.26 loss

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 21%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

Executive VP & Chief Medical Officer notifies of intention to sell stock

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Price target decreased to US$44.70

Consensus revenue estimates fall by 14%

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Investor sentiment improved over the past week

Regenxbio: A Transformative Year

Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Executive VP & Chief Financial Officer notifies of intention to sell stock